A
Anthony B. El-Khoueiry
Researcher at University of Southern California
Publications - 308
Citations - 13491
Anthony B. El-Khoueiry is an academic researcher from University of Southern California. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 41, co-authored 248 publications receiving 8874 citations. Previous affiliations of Anthony B. El-Khoueiry include University of Arkansas for Medical Sciences & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry,Bruno Sangro,Thomas Yau,Todd S. Crocenzi,Masatoshi Kudo,Chiun Hsu,Tae You Kim,Su Pin Choo,Jörg Trojan,Theodore H. Welling,Tim Meyer,Yoon-Koo Kang,Winnie Yeo,Akhil Chopra,Jeffrey Anderson,Christine Dela Cruz,Lixin Lang,Jaclyn Neely,Hao Tang,Homa Dastani,Ignacio Melero +20 more
TL;DR: Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma, and safety and tolerability for the escalation phase and objective response rate were primary endpoints.
Journal ArticleDOI
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Ghassan K. Abou-Alfa,Tim Meyer,Ann-Lii Cheng,Anthony B. El-Khoueiry,Lorenza Rimassa,Baek Yeol Ryoo,Irfan Cicin,Philippe Merle,Yen-Hsun Chen,Joong-Won Park,Jean-Frédéric Blanc,Luigi Bolondi,Heinz Josef Klümpen,Heinz Josef Klümpen,Stephen L. Chan,Vittorina Zagonel,Tiziana Pressiani,Min Hee Ryu,Alan P. Venook,Alan P. Venook,Colin Hessel,Anne E. Borgman-Hagey,Gisela Schwab,Robin Kate Kelley +23 more
TL;DR: Treatment with cabozantinib resulted in longer overall survival and progression‐free survival than placebo among patients with previously treated advanced hepatocellular carcinoma, and the rate of high‐grade adverse events in the cabozaninib group was approximately twice that observed in the placebo group.
Journal ArticleDOI
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial
Alan P. Venook,Donna Niedzwiecki,Heinz-Josef Lenz,Federico Innocenti,Briant Fruth,Jeffrey A. Meyerhardt,Deborah Schrag,Claire Greene,Bert H. O'Neil,James N. Atkins,Scott R. Berry,Blase N. Polite,Eileen M. O'Reilly,Richard M. Goldberg,Howard S. Hochster,Richard L. Schilsky,Monica M. Bertagnolli,Anthony B. El-Khoueiry,Peter Watson,Al B. Benson,Daniel Mulkerin,Robert J. Mayer,Charles D. Blanke +22 more
TL;DR: Among patients with KRAS wt untreated advanced or metastatic colorectal cancer, there was no significant difference in overall survival between the addition of cetuximab vs bevacizumab to chemotherapy as initial biologic treatment.
Journal ArticleDOI
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Thomas Yau,Yoon-Koo Kang,Tae-You Kim,Anthony B. El-Khoueiry,Armando Santoro,Bruno Sangro,Ignacio Melero,Masatoshi Kudo,Ming Mo Hou,Ana Matilla,Francesco Tovoli,Jennifer J. Knox,Aiwu Ruth He,Bassel F. El-Rayes,Mirelis Acosta-Rivera,Ho Yeong Lim,Jaclyn Neely,Yun Shen,Tami Wisniewski,Jeffrey Anderson,Chiun Hsu +20 more
TL;DR: The manageable safety profile and promising response rates observed in this study support further investigation of nivolumab plus ipilimumab as a treatment option for this patient population.
Journal ArticleDOI
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa,Ghassan K. Abou-Alfa,Teresa Macarulla,Milind Javle,Robin Kate Kelley,Sam J. Lubner,Jorge Adeva,James M. Cleary,Daniel V.T. Catenacci,Mitesh J. Borad,John Bridgewater,William P. Harris,Adrian Murphy,Do Youn Oh,Jonathan R. Whisenant,Maeve A. Lowery,Lipika Goyal,Rachna T. Shroff,Anthony B. El-Khoueiry,Bin Fan,Bin Wu,Christina X. Chamberlain,Liewen Jiang,Camelia Gliser,Shuchi Sumant Pandya,Juan W. Valle,Andrew X. Zhu,Andrew X. Zhu +27 more
TL;DR: Progression-free survival was significantly improved with ivosidenib compared with placebo, and ivOSidenib was well tolerated, and this study shows the clinical benefit of targeting IDH1 mutations in advanced,IDH1-mutant cholangiocarcinoma.